- 文档语言：英文
- 文档大小：73KB
- 文档类型：PPT
- 发布时间：2017/6/9 14:45:16
- 相关网站：internet
-
下载
- 版权说明：本站所有资源来源于网络，版权为原作者所有，本站刊载，仅限于促进医药行业发展、科技进步之目的。如本站行为侵犯了您的合法权益，请来信告知，我们将妥善处理。给您带来不便，敬请原谅。
- 幻灯介绍：
Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients Trial
Presented at
American College of Cardiology
Scientific Sessions 2005
Presented by Dr. Stuart J. Connolly
OPTIC Trial
Endpoints (1 year):
Occurrence of shock (appropriate or inappropriate)
OPTIC Trial
Presented at ACC Scientific Sessions 2005
412 patients receiving a St. Jude Medical dual chamber ICD,
with presence of one of the following: 1) spontaneous ventricular tachycardia (VT);
or 2) left ventricular (LV) ejection fraction ≤40% with either spontaneous ventricular fibrillation (VF) or inducible VT or VF.
Randomized
Beta-Blocker Alone Metoprolol, Carvedolol, or Bisoprolol
Sotalol
160 mg/day
Beta-Blocker
plus Amiodarone
800 mg load plus
200 mg/day
Presented at ACC Scientific Sessions 2005
Baseline clinical characteristics were similar between the treatment groups, with 80% of patients having had a prior MI, 29% having inducible VT or VF and 71% spontaneous VT or VF.
Any Shock at 1 Year
Beta-blocker
Sotalol
Beta-Blocker
w/ Amiodarone
p=0.055
p<0.0001
p=0.015
Any Shock at 1 Year
Excluding Shocks During First 21 Days
Beta-blocker
Sotalol
Beta-Blocker
w/ Amiodarone
p=0.014
p<0.0001
p=0.0057
OPTIC Trial
Presented at ACC Scientific Sessions 2005
Mean number of shocks per patient was 4.32 in the beta-blocker alone group, 0.93 in the sotalol group, and 0.51 of the amiodarone plus beta-blocker group. Adverse events were similar in the three groups.
Appropriate Shocks
Beta-blocker
Sotalol
Beta-Blocker
w/ Amiodarone
p=0.0036
Inappropriate Shocks
Beta-blocker
Sotalol
Beta-Blocker
w/ Amiodarone
p=0.20
p=0.0055
OPTIC Trial
Among patients receiving a dual chamber ICD for spontaneous or inducible VT or VF, sotalol therapy and amiodarone plus beta-blocker therapy were associated with reductions in shocks at 1 year compared with beta-blocker therapy alone.
The reductions in the amiodarone plus beta-blocker group were greater than the sotalol group.
The addition of amiodarone or sotalol was associated with reductions in shock without an increase in adverse events, suggesting these therapies may improve the quality of life in patients implanted with an ICD.
OPTIC Trial: Summary
Presented at ACC Scientific Sessions 2005